| scholarly article | Q13442814 |
| P356 | DOI | 10.1161/HYPERTENSIONAHA.107.091264 |
| P698 | PubMed publication ID | 17592071 |
| P50 | author | Vanesa Esteban | Q38641526 |
| Luis M Blanco-Colio | Q55542660 | ||
| Marta Ruiz-Ortega | Q56616783 | ||
| Juan Rodriguez-Vita | Q58774280 | ||
| Elsa Sanchez-Lopez | Q61162439 | ||
| P2093 | author name string | Jesús Egido | |
| Raquel Rodrigues-Díez | |||
| Mónica Rupérez | |||
| Juan José Plaza | |||
| Gisselle Carvajal | |||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 377-383 | |
| P577 | publication date | 2007-06-25 | |
| P1433 | published in | Hypertension | Q5958695 |
| P1476 | title | HMG-CoA reductase inhibitors decrease angiotensin II-induced vascular fibrosis: role of RhoA/ROCK and MAPK pathways | |
| P478 | volume | 50 |
| Q36042695 | Atorvastatin and sildenafil decrease vascular TGF-β levels and MMP-2 activity and ameliorate arterial remodeling in a model of renovascular hypertension |
| Q34776189 | Atorvastatin upregulates regulatory T cells and reduces clinical disease activity in patients with rheumatoid arthritis |
| Q38079105 | Connective tissue growth factor (CCN2) in blood vessels |
| Q52633077 | Connective tissue growth factor expression after angiotensin II exposure is dependent on transforming growth factor-β signaling via the canonical Smad-dependent pathway in hypertensive induced myocardial fibrosis. |
| Q37328067 | Effect of simvastatin in the autonomic system is dependent on the increased gain/sensitivity of the baroreceptors. |
| Q33393631 | Essential role of TGF-beta/Smad pathway on statin dependent vascular smooth muscle cell regulation |
| Q33694487 | Extracellular matrix molecules: potential targets in pharmacotherapy. |
| Q38802968 | Inhibition of Angiotensin II-Induced Cardiac Fibrosis by Atorvastatin in Adiponectin Knockout Mice |
| Q39237720 | Lysophosphatidic acid (LPA) as a pro-fibrotic and pro-oncogenic factor: a pivotal target to improve the radiotherapy therapeutic index |
| Q38104354 | Molecular and genetic advances in the regeneration of the intervertebral disc. |
| Q39960357 | Pharmacological modulation of epithelial mesenchymal transition caused by angiotensin II. Role of ROCK and MAPK pathways. |
| Q38043896 | Rho GTPases in pulmonary vascular dysfunction |
| Q28544668 | Rho-kinase inhibition ameliorates metabolic disorders through activation of AMPK pathway in mice |
| Q39639606 | Rho-kinase mediates TNF-α-induced MCP-1 expression via p38 MAPK signaling pathway in mesangial cells |
| Q34362144 | Rho/Rho-associated coiled-coil forming kinase pathway as therapeutic targets for statins in atherosclerosis |
| Q33702090 | Rosuvastatin attenuates the elevation in blood pressure induced by overexpression of human C-reactive protein. |
| Q38649864 | Rosuvastatin improves endothelial function in db/db mice: role of angiotensin II type 1 receptors and oxidative stress. |
| Q35179736 | Rosuvastatin prevents proteinuria and renal inflammation in nitric oxide-deficient rats |
| Q35711172 | Simvastatin Increases Fibulin-2 Expression in Human Coronary Artery Smooth Muscle Cells via RhoA/Rho-Kinase Signaling Pathway Inhibition |
| Q37110500 | Simvastatin Reduces Capsular Fibrosis around Silicone Implants. |
| Q34921512 | Simvastatin reduces fibrosis and protects against muscle weakness after massive rotator cuff tear |
| Q43057770 | Simvastatin reduces pressor response to centrally administered angiotensin II. |
| Q35723980 | Small-nucleic-acid-based therapeutic strategy targeting the transcription factors regulating the vascular inflammation, remodeling and fibrosis in atherosclerosis |
| Q36088110 | Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials. |
| Q26776067 | Statins in Asthma: Potential Beneficial Effects and Limitations |
| Q41369308 | Statins inhibit angiotensin II/Smad pathway and related vascular fibrosis, by a TGF-β-independent process. |
| Q41833192 | Strategies for blocking the fibrogenic actions of connective tissue growth factor (CCN2): From pharmacological inhibition in vitro to targeted siRNA therapy in vivo |
| Q53648300 | Waon therapy attenuates cardiac hypertrophy and promotes myocardial capillary growth in hypertensive rats: a comparative study with fluvastatin. |
| Q39213241 | Xiamenmycin attenuates hypertrophic scars by suppressing local inflammation and the effects of mechanical stress. |
Search more.